IL163594A0 - Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent - Google Patents
Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solventInfo
- Publication number
- IL163594A0 IL163594A0 IL16359403A IL16359403A IL163594A0 IL 163594 A0 IL163594 A0 IL 163594A0 IL 16359403 A IL16359403 A IL 16359403A IL 16359403 A IL16359403 A IL 16359403A IL 163594 A0 IL163594 A0 IL 163594A0
- Authority
- IL
- Israel
- Prior art keywords
- calcium
- atorvastatinhemi
- processes
- organic solvent
- essentially free
- Prior art date
Links
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 title 2
- 239000003960 organic solvent Substances 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35849702P | 2002-02-19 | 2002-02-19 | |
PCT/US2003/005216 WO2003070665A2 (fr) | 2002-02-19 | 2003-02-19 | Processus destines a la desolvation des solvates de demi-calcium d'atorvastatine et demi-calcium d'atorvastatine sensiblement exempt de solvant organique |
Publications (1)
Publication Number | Publication Date |
---|---|
IL163594A0 true IL163594A0 (en) | 2005-12-18 |
Family
ID=27757749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16359403A IL163594A0 (en) | 2002-02-19 | 2003-02-19 | Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent |
Country Status (15)
Country | Link |
---|---|
US (2) | US7122681B2 (fr) |
EP (1) | EP1465901A4 (fr) |
JP (4) | JP4422488B2 (fr) |
KR (3) | KR20090045420A (fr) |
CN (1) | CN100379723C (fr) |
AU (1) | AU2003213171A1 (fr) |
CA (1) | CA2475123A1 (fr) |
HR (1) | HRP20040767A2 (fr) |
IL (1) | IL163594A0 (fr) |
IS (1) | IS7407A (fr) |
MX (1) | MXPA04007995A (fr) |
NO (1) | NO20043829L (fr) |
PL (1) | PL372241A1 (fr) |
WO (1) | WO2003070665A2 (fr) |
ZA (1) | ZA200406229B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) * | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
WO2006008091A2 (fr) * | 2004-07-16 | 2006-01-26 | Lek Pharmaceuticals D.D. | Produits de degradation oxydante du calcium d'atorvastatine |
DE202005020766U1 (de) * | 2004-07-22 | 2006-10-05 | Teva Pharmaceutical Industries Ltd. | Neue Kristallformen von Atorvastatin-Hemi-Calcium |
EP1784408A1 (fr) * | 2004-08-25 | 2007-05-16 | Pfizer Limited | Triazolobenzodiazepines et leur utilisation en tant qu'antagonistes de la vasopressine |
WO2006039441A2 (fr) * | 2004-09-30 | 2006-04-13 | Dr. Reddy's Laboratories Ltd. | Atorvastatine calcique amorphe |
CZ2007772A3 (cs) * | 2005-04-08 | 2008-02-27 | EGIS GYOGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | Nová krystalická polymorfní forma hemivápenaté soli atorvastatinu |
BRPI0610344A2 (pt) * | 2005-12-13 | 2016-11-29 | Teva Pharma | forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal |
US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IT1390848B1 (it) * | 2008-07-31 | 2011-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
PL3630744T3 (pl) | 2017-05-23 | 2023-05-15 | H. Lundbeck A/S | Pirazolowe inhibitory magl |
JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US444129A (en) * | 1891-01-06 | Henry l | ||
US4444129A (en) | 1982-11-05 | 1984-04-24 | Lecorp | Method of drying fine coal particles |
DE3306250A1 (de) * | 1983-02-23 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | Sphaerische einkristalle fuer pharmazeutische zwecke |
JPS59167676A (ja) | 1983-03-11 | 1984-09-21 | 株式会社 大川原製作所 | 多室型流動層乾燥機 |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
DE69616808T2 (de) * | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
IL149681A0 (en) | 1999-11-17 | 2002-11-10 | Teva Pharma | Polymorphic form of atorvstatin calcium |
HUP0203708A3 (en) | 1999-12-17 | 2003-11-28 | Warner Lambert Res & Dev Ie | A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt |
CA2391357C (fr) | 1999-12-17 | 2009-01-06 | Warner Lambert Research And Development Ireland Limited | Procede pour produire de l'atorvastatine calcique cristallin |
MXPA03003900A (es) * | 2000-11-03 | 2005-02-17 | Teva Pharma | Forma vii de hemicalcio de atorvastatina. |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2622477A1 (fr) | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Formes cristallines d'atorvastatine |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
IN190564B (fr) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
PL367943A1 (en) * | 2001-06-29 | 2005-03-07 | Warner-Lambert Company Llc | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA2454500C (fr) | 2001-07-30 | 2009-11-10 | Dr. Reddy's Laboratories Ltd. | Formes cristallines vi et vii de calcium d'atorvastatine |
CA2456095C (fr) | 2001-08-31 | 2010-05-11 | Morepen Laboratories Ltd. | Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1) |
DE03713610T1 (de) | 2002-02-15 | 2005-10-20 | Teva Pharma | Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium |
-
2003
- 2003-02-19 KR KR1020097007465A patent/KR20090045420A/ko not_active Application Discontinuation
- 2003-02-19 KR KR10-2004-7012804A patent/KR20040086397A/ko not_active Application Discontinuation
- 2003-02-19 CN CNB038040913A patent/CN100379723C/zh not_active Expired - Fee Related
- 2003-02-19 CA CA002475123A patent/CA2475123A1/fr not_active Abandoned
- 2003-02-19 EP EP03709217A patent/EP1465901A4/fr not_active Withdrawn
- 2003-02-19 IL IL16359403A patent/IL163594A0/xx unknown
- 2003-02-19 WO PCT/US2003/005216 patent/WO2003070665A2/fr active Application Filing
- 2003-02-19 JP JP2003569575A patent/JP4422488B2/ja not_active Expired - Fee Related
- 2003-02-19 US US10/370,424 patent/US7122681B2/en not_active Expired - Fee Related
- 2003-02-19 KR KR1020097007464A patent/KR20090045419A/ko not_active Application Discontinuation
- 2003-02-19 PL PL03372241A patent/PL372241A1/xx unknown
- 2003-02-19 MX MXPA04007995A patent/MXPA04007995A/es active IP Right Grant
- 2003-02-19 AU AU2003213171A patent/AU2003213171A1/en not_active Abandoned
-
2004
- 2004-08-04 ZA ZA200406229A patent/ZA200406229B/en unknown
- 2004-08-17 IS IS7407A patent/IS7407A/is unknown
- 2004-08-25 HR HRP20040767 patent/HRP20040767A2/hr not_active Application Discontinuation
- 2004-09-13 NO NO20043829A patent/NO20043829L/no not_active Application Discontinuation
-
2006
- 2006-10-02 US US11/542,339 patent/US20070027328A1/en not_active Abandoned
-
2009
- 2009-02-26 JP JP2009044173A patent/JP2009143957A/ja active Pending
- 2009-07-17 JP JP2009169170A patent/JP2009235100A/ja active Pending
-
2013
- 2013-03-13 JP JP2013050939A patent/JP2013136630A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1465901A4 (fr) | 2006-02-01 |
KR20090045419A (ko) | 2009-05-07 |
PL372241A1 (en) | 2005-07-11 |
ZA200406229B (en) | 2006-06-28 |
KR20090045420A (ko) | 2009-05-07 |
US7122681B2 (en) | 2006-10-17 |
HRP20040767A2 (en) | 2004-12-31 |
CN100379723C (zh) | 2008-04-09 |
CN1633439A (zh) | 2005-06-29 |
AU2003213171A1 (en) | 2003-09-09 |
US20030216584A1 (en) | 2003-11-20 |
JP2013136630A (ja) | 2013-07-11 |
IS7407A (is) | 2004-08-17 |
JP2005523285A (ja) | 2005-08-04 |
KR20040086397A (ko) | 2004-10-08 |
EP1465901A2 (fr) | 2004-10-13 |
JP2009235100A (ja) | 2009-10-15 |
WO2003070665A3 (fr) | 2004-02-12 |
CA2475123A1 (fr) | 2003-08-28 |
US20070027328A1 (en) | 2007-02-01 |
WO2003070665A2 (fr) | 2003-08-28 |
JP2009143957A (ja) | 2009-07-02 |
MXPA04007995A (es) | 2004-11-26 |
JP4422488B2 (ja) | 2010-02-24 |
NO20043829L (no) | 2004-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL163594A0 (en) | Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent | |
EG24716A (en) | Combination of organic compounds | |
GB0212412D0 (en) | Combination of organic compounds | |
AU2003237121A1 (en) | Pyrrole derivatives as inhibitors of erk2 and uses thereof | |
PL376575A1 (pl) | Podstawione związki heterocykliczne oraz sposoby wykorzystania | |
EP1625223A4 (fr) | Procedes chimioenzymatiques de synthese de statines et d'intermediaires de statine | |
HK1080549A1 (zh) | 有關 調節者的篩選方法 | |
IL161258A0 (en) | Heterocyclic compounds and methods of use | |
EP1625140A4 (fr) | Composes immunomodulateurs ramifies et leur procedes d'utilisation | |
AU2003247656A1 (en) | Oxidation of organic compounds | |
AU2003301451A1 (en) | Component capable of being cooled | |
AU2002233755A1 (en) | Electronic apparatus and function extension device for extending function of electronic apparatus | |
IL174927A0 (en) | Use of organic compounds | |
GB0326520D0 (en) | Molluscicidal and anti-barnacle compounds | |
IL180708A0 (en) | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation | |
AU2002214024A1 (en) | Novel diaminopyrazole derivatives and dyes containing said compounds | |
AU2003250858A1 (en) | Use of organic compounds | |
IL161300A0 (en) | Methods of screening for toxicity of test compounds | |
GB0303615D0 (en) | Use of organic compounds | |
AU2003205953A1 (en) | Method of storing data-elements | |
AU2003286024A8 (en) | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | |
AU2003268738A8 (en) | Processes for preparation of organic compounds | |
PL353419A1 (en) | Organic fertiliser and method of obtaining same | |
GB0011407D0 (en) | Synthesis of substituted prolines | |
AU2003242773A1 (en) | Use of organic compounds |